HOOKIPA Pharma (NASDAQ:HOOK) Stock Price Down 8.8% – Here’s Why

HOOKIPA Pharma Inc. (NASDAQ:HOOK)’s share price was down 8.8% during trading on Monday . The company traded as low as $1.03 and last traded at $1.04. Approximately 398,914 shares were traded during mid-day trading, an increase of 374% from the average daily volume of 84,197 shares. The stock had previously closed at $1.14.

HOOKIPA Pharma Trading Down 8.8%

The company’s 50 day simple moving average is $1.38 and its 200 day simple moving average is $1.41. The stock has a market capitalization of $12.68 million, a PE ratio of -0.18 and a beta of 0.89.

HOOKIPA Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.62). HOOKIPA Pharma had a negative net margin of 785.66% and a negative return on equity of 120.09%. As a group, analysts predict that HOOKIPA Pharma Inc. will post -1.75 EPS for the current year.

Institutional Trading of HOOKIPA Pharma

A number of hedge funds have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in shares of HOOKIPA Pharma in the 4th quarter valued at $31,000. Squarepoint Ops LLC acquired a new stake in shares of HOOKIPA Pharma during the fourth quarter worth $104,000. Finally, Gilead Sciences Inc. bought a new position in shares of HOOKIPA Pharma during the fourth quarter worth about $3,771,000. 63.88% of the stock is owned by institutional investors.

About HOOKIPA Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.